<DOC>
	<DOCNO>NCT01281280</DOCNO>
	<brief_summary>This post-market , open observational long-term effectiveness follow-up study participant drug-resistant epilepsy partial-onset seizure previously enrol randomize control trial ( PuLsE ) compare Best Medical Practice without adjunctive Vagus Nerve Stimulation Therapy .</brief_summary>
	<brief_title>PuLsE 2-Observational Long-Term Effectiveness Follow-Up Study PuLsE 1</brief_title>
	<detailed_description>In 2005 Cyberonics , Inc. initiate PuLsE : open , prospective , randomize , parallel group study directly compare Best Medical Practice without adjunctive VNS Therapy . In July 2008 , decision make discontinue study due low expect enrolment , impair possibility meet primary objective appropriate statistical power . However , relatively large number participant ( n=121 ) randomize original PuLsE study offer possibility generate scientifically valuable original finding additional follow-up data gather . After consultation PuLsE Investigators , Cyberonics decide implement observational long-term follow-up participant enrol original PuLsE study .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Drug Resistant Epilepsy</mesh_term>
	<criteria>To eligible study , participant must meet following criterion : 1 . Participant must randomize original PuLsE study . 2 . Participant must baseline data original PuLsE study . 3 . Participant able give accurate seizure count , health outcome information , complete study instrument minimal assistance . 4 . Participant legal guardian understands study procedure voluntarily sign informed consent PuLsE 2 accordance institutional local regulatory policy . The presence follow exclude participant study : 1 . Participant history noncompliance completion seizure diary . 2 . Participant currently use , expect use study , shortwave diathermy , microwave diathermy , therapeutic ultrasound diathermy . 3 . Participant expect require full body magnetic resonance image clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>PuLsE 2 , Drug-resistant Epilepsy Partial-onset Seizures</keyword>
</DOC>